{
  "generated": "2025-11-06T07:16:50.747477+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/metabolic/rapamycin-alternative-long-gen-0659/longevity/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "LONG-GEN-0659_01",
      "year": 2018,
      "design": "randomized controlled trial",
      "journal": "longevity_journal",
      "outcome": "nad_boosting",
      "population": "Adults with nad boosting concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/rapamycin-alternative-long-gen-0659-01",
      "url": "https://doi.org/10.1234/rapamycin-alternative-long-gen-0659-01",
      "citation": "LONG-GEN-0659_01 (2018); Journal: longevity_journal; Design: randomized controlled trial; Population: Adults with nad boosting concerns; Outcome: nad_boosting; DOI: 10.1234/rapamycin-alternative-long-gen-0659-01; Adverse Events: None reported."
    },
    {
      "study_id": "LONG-GEN-0659_02",
      "year": 2019,
      "design": "randomized controlled trial",
      "journal": "longevity_journal",
      "outcome": "nad_boosting",
      "population": "Adults with nad boosting concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/rapamycin-alternative-long-gen-0659-02",
      "url": "https://doi.org/10.1234/rapamycin-alternative-long-gen-0659-02",
      "citation": "LONG-GEN-0659_02 (2019); Journal: longevity_journal; Design: randomized controlled trial; Population: Adults with nad boosting concerns; Outcome: nad_boosting; DOI: 10.1234/rapamycin-alternative-long-gen-0659-02; Adverse Events: None reported."
    },
    {
      "study_id": "LONG-GEN-0659_03",
      "year": 2020,
      "design": "randomized controlled trial",
      "journal": "longevity_journal",
      "outcome": "nad_boosting",
      "population": "Adults with nad boosting concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/rapamycin-alternative-long-gen-0659-03",
      "url": "https://doi.org/10.1234/rapamycin-alternative-long-gen-0659-03",
      "citation": "LONG-GEN-0659_03 (2020); Journal: longevity_journal; Design: randomized controlled trial; Population: Adults with nad boosting concerns; Outcome: nad_boosting; DOI: 10.1234/rapamycin-alternative-long-gen-0659-03; Adverse Events: None reported."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/rapamycin-alternative-long-gen-0659-01",
      "study_ids": [
        "LONG-GEN-0659_01"
      ],
      "primary_study_id": "LONG-GEN-0659_01",
      "url": "https://doi.org/10.1234/rapamycin-alternative-long-gen-0659-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/rapamycin-alternative-long-gen-0659-02",
      "study_ids": [
        "LONG-GEN-0659_02"
      ],
      "primary_study_id": "LONG-GEN-0659_02",
      "url": "https://doi.org/10.1234/rapamycin-alternative-long-gen-0659-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/rapamycin-alternative-long-gen-0659-03",
      "study_ids": [
        "LONG-GEN-0659_03"
      ],
      "primary_study_id": "LONG-GEN-0659_03",
      "url": "https://doi.org/10.1234/rapamycin-alternative-long-gen-0659-03"
    }
  ],
  "manifest_hash": "sha256:1828ffa5ea4682eb23ead4f28176eb3f19b487f180bd547a484363f8192c1788"
}
